CTA
NBIX icon

Chesley Taft & Associates’s Neurocrine Biosciences NBIX Stock Holding History

Chesley Taft & Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,500
Closed -$1.03M – 315
2024
Q1 		$1.03M Buy
+7,500
New +$1.02M 0.05% 183

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Chesley Taft & Associates's NBIX Position: Q2 2024 in Review

Chesley Taft & Associates sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 7,500 shares — an estimated $1.03M sold.

Chesley Taft & Associates first reported a position in NBIX in Q1 2024 and held it in 1 quarter. The position peaked at $1.03M in Q1 2024. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • Chesley Taft & Associates reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • Chesley Taft & Associates sold 7,500 Neurocrine Biosciences shares in Q2 2024, an estimated $1.03M.
  • Chesley Taft & Associates first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 1 quarter.
  • Chesley Taft & Associates's Neurocrine Biosciences position peaked at $1.03M in Q1 2024.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Chesley Taft & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.